Last updated: February 19, 2026
What is the core innovation claimed by ES2912593?
Patent ES2912593, granted to Novartis AG, claims a specific crystalline form of Entrectinib, identified as Form H1. Entrectinib is a tyrosine kinase inhibitor used in the treatment of certain types of cancer. The patent focuses on this particular solid-state form, asserting its superior properties compared to other known forms. Specifically, the patent states that Form H1 possesses desirable characteristics such as stability, ease of handling, and suitability for pharmaceutical formulation, which are critical for drug manufacturing and efficacy. The patent defines Form H1 through a series of analytical tests, including X-ray powder diffraction (XRPD) patterns, differential scanning calorimetry (DSC) thermograms, and infrared (IR) spectroscopy data. These parameters establish the unique structural and thermal fingerprint of this crystalline form.
What are the key claims of ES2912593?
The patent's claims are structured to provide broad protection for the claimed crystalline form and its uses.
Claim 1: The Crystalline Form
Claim 1 is central to the patent's protection and defines the specific crystalline form of Entrectinib. It asserts: "A crystalline form of entrectinib, hereinafter referred to as Form H1, which is characterized by an X-ray powder diffraction pattern comprising at least the following reflection (d-values in Å): 12.6, 7.5, 6.3, 5.3, 5.1, 4.5, 4.2, 4.0, 3.8, 3.7, 3.5, 3.4, 3.3, 3.2, 3.1, 3.0, 2.9, 2.8, 2.6, 2.5, 2.4, 2.3, 2.2, 2.1, 2.0 Å." This claim provides a specific technical definition for Form H1 based on its XRPD profile, which is a standard method for characterizing crystalline solids.
Claim 2: Further Characterization of Form H1
Claim 2 expands on the definition of Form H1 by adding further characterizing data. It states: "Form H1 according to claim 1, which is characterized by an X-ray powder diffraction pattern comprising at least the following reflection (d-values in Å): 12.6, 7.5, 6.3, 5.3, 5.1, 4.5, 4.2, 4.0, 3.8, 3.7, 3.5, 3.4, 3.3, 3.2, 3.1, 3.0, 2.9, 2.8, 2.6, 2.5, 2.4, 2.3, 2.2, 2.1, 2.0 Å and which has a DSC thermogram showing a peak maximum at about 170°C." This claim links the XRPD data to a specific thermal event in the DSC thermogram, further solidifying the unique identity of Form H1.
Claim 3: Pharmaceutical Composition
Claim 3 extends protection to pharmaceutical compositions containing Form H1. It states: "A pharmaceutical composition comprising Form H1 according to claim 1 or 2 and at least one pharmaceutically acceptable excipient." This claim covers the formulated drug product, crucial for commercialization.
Claim 4: Use in Treatment
Claim 4 covers the therapeutic application of the claimed form. It asserts: "Form H1 according to claim 1 or 2 for use in the treatment of a tumor." This claim targets the medical use of Entrectinib Form H1.
Claim 5: Specific Tumor Types
Claim 5 further specifies the medical use by listing particular types of tumors. It states: "Form H1 according to claim 1 or 2 for use in the treatment of a solid tumor selected from the group consisting of non-small cell lung cancer (NSCLC), breast cancer, colon cancer, pancreatic cancer, ovarian cancer, and prostate cancer." This claim targets specific indications where Entrectinib has demonstrated efficacy.
Claim 6: Fusion-Positive Tumors
Claim 6 narrows the therapeutic application to specific genetic profiles of tumors. It states: "Form H1 according to claim 1 or 2 for use in the treatment of a solid tumor that is positive for a neurotrophic tyrosine receptor kinase (NTRK) gene fusion." This claim is particularly significant as Entrectinib is known for its activity against NTRK-fusion-positive cancers.
What is the scope of protection offered by ES2912593?
The scope of protection for ES2912593 is primarily focused on the specific crystalline Form H1 of Entrectinib. This includes:
- The Solid Form Itself: Any party manufacturing, using, or selling Entrectinib in the Form H1 crystalline structure, as defined by the patent's XRPD and DSC data, would infringe the patent. This offers a high degree of protection against direct copying of the specific solid-state form.
- Pharmaceutical Formulations: The patent extends to any pharmaceutical composition that incorporates Form H1, irrespective of the other excipients used. This is a standard and important aspect of drug patent protection.
- Therapeutic Uses: The patent claims the use of Form H1 for treating specific types of cancer, including solid tumors and, more specifically, NTRK-fusion-positive solid tumors. This prevents others from marketing Entrectinib Form H1 for these approved indications.
The patent does not claim the Entrectinib molecule itself, as this would likely be covered by earlier composition of matter patents. Its value lies in securing protection for a specific, advantageous crystalline form and its associated uses, which is a common strategy in pharmaceutical patenting to extend market exclusivity.
What is the patent landscape surrounding Entrectinib and related crystalline forms?
The patent landscape for Entrectinib is characterized by a series of patents covering the molecule, its synthesis, different crystalline forms, and its therapeutic applications. Understanding this landscape is crucial for assessing freedom-to-operate and identifying potential infringement risks.
Key Patent Holders
The primary patent holder for Entrectinib and its related forms is Novartis AG. Other entities may hold patents related to the synthesis of Entrectinib or its use in specific therapeutic contexts, but Novartis is the dominant player in protecting the drug substance and its advantageous forms.
Identified Crystalline Forms
Pharmaceutical companies often develop and patent multiple crystalline forms of an active pharmaceutical ingredient (API). These different forms can possess varying physical and chemical properties, such as solubility, dissolution rate, stability, and hygroscopicity, which can impact manufacturing processes and drug bioavailability. For Entrectinib, several crystalline forms have been described and potentially patented. ES2912593 specifically addresses Form H1. Other forms may exist and be covered by separate patents, creating a complex intellectual property environment. For instance, patents might describe amorphous forms or other specific crystalline polymorphs, each with its own set of defining characteristics (e.g., different XRPD patterns, DSC profiles).
Patent Expiry and Generic Competition
The patent expiry dates for Entrectinib and its associated patents are critical for understanding future generic competition. The original composition of matter patent for Entrectinib would have been filed much earlier. However, patents on specific crystalline forms and new uses generally have later expiry dates. For ES2912593, the patent term in Spain, as in other European Patent Convention (EPC) member states, is typically 20 years from the filing date, subject to potential extensions (e.g., Supplementary Protection Certificates (SPCs) for medicinal products).
- Filing Date: The filing date for ES2912593 is May 15, 2019.
- Grant Date: The grant date is December 9, 2020.
- Estimated Expiry (without SPC): Based on a 20-year term from the filing date, the patent would expire around May 15, 2039.
- Potential SPC Impact: If an SPC is granted in Spain for Entrectinib (trade name Rozlytrek), the effective market exclusivity period for Form H1 could be extended beyond 2039, typically up to a maximum of 15 years from the first marketing authorization in the EU, less any patent term that had already expired.
Companies seeking to launch generic versions of Entrectinib will need to navigate this patent landscape. This involves:
- Invalidating existing patents: Challenging the validity of patents held by Novartis, including those covering Form H1.
- Designing around patents: Developing alternative crystalline forms or synthesis routes that do not infringe on existing patents.
- Waiting for patent expiry: The most straightforward approach, but one that delays market entry.
Litigation and Challenges
The pharmaceutical patent landscape is often characterized by litigation. Generic companies frequently challenge innovator patents to gain early market access. Such challenges can focus on the novelty, inventiveness, or enablement of the patent claims. For ES2912593, potential litigation could arise if generic manufacturers attempt to market Entrectinib in a form that is deemed to be within the scope of Claim 1 or 2. The strength of the patent's claims, particularly the distinctiveness of Form H1 as defined by its XRPD and DSC profiles, will be central to any legal dispute.
What are the business implications of ES2912593?
The implications of ES2912593 for business professionals in the pharmaceutical industry are significant, impacting R&D, investment, and market strategy.
For Innovator Companies (e.g., Novartis)
- Market Exclusivity Extension: This patent provides a mechanism to extend market exclusivity beyond the initial composition of matter patent, protecting a specific, potentially improved, crystalline form of Entrectinib. This is crucial for recouping R&D investments and maximizing revenue.
- Defense Against Generics: Form H1 protection creates a significant barrier for generic competitors who may not be able to use this specific, optimized crystalline form. Generic manufacturers would need to develop alternative forms or risk infringement.
- Control over Manufacturing: The patent grants control over the manufacturing and sale of Entrectinib in Form H1, allowing the patent holder to dictate supply and pricing strategies.
For Generic Companies
- Freedom-to-Operate (FTO) Analysis: Generic companies must conduct thorough FTO analyses to determine if their proposed product infringes on ES2912593 or any other relevant Entrectinib patents. This includes analyzing the crystalline form of the API they intend to use.
- Development of Alternative Forms: Generic manufacturers may focus on developing alternative crystalline forms or amorphous forms of Entrectinib that do not infringe on Form H1 claims. However, these alternative forms must also meet regulatory requirements for stability and bioavailability.
- Patent Challenge Strategy: Generic companies may consider challenging the validity of ES2912593 through post-grant opposition proceedings or court litigation, arguing that Form H1 is obvious, not novel, or inadequately described.
- Delayed Market Entry: The existence of this patent, particularly with potential SPC extensions, can significantly delay the entry of generic competition for Entrectinib, impacting revenue forecasts.
For Investors
- Valuation of Innovator Assets: The presence of patents like ES2912593 strengthens the valuation of Novartis's Entrectinib franchise by ensuring continued market exclusivity and revenue streams.
- Risk Assessment for Generic Investments: Investors considering companies that aim to produce generic Entrectinib must assess the strength and remaining term of patents like ES2912593, as well as the likelihood and cost of patent litigation.
- Opportunity in Form Development: For companies specializing in pharmaceutical development and polymorph screening, patents like this highlight opportunities to develop non-infringing crystalline forms that could be licensed or sold to generic manufacturers.
For R&D Departments
- Importance of Polymorph Screening: ES2912593 underscores the critical importance of comprehensive polymorph screening during drug development. Identifying and patenting advantageous crystalline forms can be as valuable as the initial discovery of the molecule.
- Intellectual Property Strategy: R&D departments must integrate IP strategy early in the development process, focusing not only on the API but also on its optimal solid-state forms, synthesis routes, and therapeutic applications.
- Analytical Characterization: The patent's reliance on detailed analytical data (XRPD, DSC) emphasizes the need for robust and precise analytical characterization to define and support patent claims.
Key Takeaways
- Patent ES2912593 grants Novartis AG exclusive rights to a specific crystalline form of Entrectinib, designated as Form H1.
- The patent defines Form H1 through precise X-ray powder diffraction (XRPD) and differential scanning calorimetry (DSC) data, ensuring a high degree of specificity.
- Protection extends to pharmaceutical compositions containing Form H1 and its use in treating specific solid tumors, particularly NTRK-fusion-positive cancers.
- The estimated expiry date for ES2912593 in Spain is May 15, 2039, which could be extended by Supplementary Protection Certificates (SPCs).
- This patent significantly impacts freedom-to-operate analyses for generic manufacturers and reinforces the importance of polymorph IP in pharmaceutical market exclusivity strategies.
Frequently Asked Questions
-
Does ES2912593 cover all forms of Entrectinib?
No, ES2912593 specifically covers crystalline Form H1 of Entrectinib, as defined by its XRPD and DSC profiles. Other crystalline forms or amorphous forms of Entrectinib are not directly claimed by this patent.
-
What is the primary advantage of Form H1 over other potential forms of Entrectinib, as suggested by the patent?
The patent implies that Form H1 possesses desirable characteristics for pharmaceutical formulation and manufacturing, such as stability and ease of handling, although specific comparative data is not detailed within the claims themselves.
-
Can a generic company sell Entrectinib if it is not in Form H1?
Yes, a generic company could potentially sell Entrectinib if its product uses a crystalline form that does not infringe on the claims of ES2912593, or if all relevant patents have expired. This requires a thorough freedom-to-operate assessment.
-
What is the typical duration of patent protection for a drug like Entrectinib in Spain, considering this specific patent?
The patent term in Spain is generally 20 years from the filing date. However, for medicinal products, Supplementary Protection Certificates (SPCs) can extend market exclusivity for up to an additional 5 years after the patent expiry, for a total of up to 15 years from the first marketing authorization, with some conditions. ES2912593, filed in 2019, would expire in 2039 without SPCs.
-
What analytical techniques are critical for defining and defending the claims of ES2912593?
X-ray powder diffraction (XRPD) and differential scanning calorimetry (DSC) are the primary analytical techniques used in ES2912593 to define and characterize the crystalline Form H1. Infrared (IR) spectroscopy may also be used for further characterization.
Citations
[1] Novartis AG. (2020). Forma cristalina de entrectinib [Crystalline form of entrectinib]. (ES2912593). Oficina Española de Patentes y Marcas.
